 |
|
|
|
|
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Syndax Pharmaceuticals Inc.
| | | | | Phone: | (646) 690-7620 | | Fax: | (212) 867-5902 | | Year Established: | 2005 | | Ticker: | SNDX | | Exchange: | NASDAQ | | Main Contact: | Briggs W. Morrison, M.D., CEO | | | | Other Contacts: | Richard P. Shea, CFO
Peter Ordentlich, Ph.D., CSO & Founder
Michael L. Meyers, M.D., Ph.D., CMO
Michael A. Metzger, President & COO
| | | | Company Description | | Syndaxis is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody. | |
|
|
|
|
|
|
|
